18 and older, any sex, with Peripheral Pulmonary Lesions. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Diagnostic YieldPrimary· 7 days post-enrollment
Diagnostic yield is defined as the proportion of procedures that results in acquisition of lesional tissue. Lesional tissue is defined by the presence of histopathological findings that readily explain the presence of a pulmonary lesion.
The following common histopathological findings are pre-specified as lesional:
i. Malignant ii. "Specific benign" findings accounting for the presence of a PPL
1. organizing pneumonia, or
2. frank purulence/robust neutrophilic inflammation, or
3. granulomatous inflammation, or
4. other specific benign finding findings such as hamartoma, amyloidoma or other
Group
Value
95% CI
ILLUMISITE™ Platform (EMN Bronchoscopy)
157
Ion™ Endoluminal System (SSCB Bronchoscopy)
158
Duration of ProcedureSecondary· Duration of procedure, approximately 60 minutes
Defined as time from the start of airway registration to the removal of the bronchoscope after completion of navigation procedures
Group
Value
95% CI
ILLUMISITE™ Platform (EMN Bronchoscopy)
32.0
25.0 – 43.3
Ion™ Endoluminal System (SSCB Bronchoscopy)
37.0
29.0 – 48.0
Adverse events — posted to ClinicalTrials.gov
Time frame: 7 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is an investigator-initiated, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the Ion™ Endoluminal System (SSCB) to the ILLUMISITE™ Platform (EMN bronchoscopy) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05705544.